BR112013024196A2 - complexos de gálio, composições farmacêuticas e métodos de uso - Google Patents
complexos de gálio, composições farmacêuticas e métodos de usoInfo
- Publication number
- BR112013024196A2 BR112013024196A2 BR112013024196A BR112013024196A BR112013024196A2 BR 112013024196 A2 BR112013024196 A2 BR 112013024196A2 BR 112013024196 A BR112013024196 A BR 112013024196A BR 112013024196 A BR112013024196 A BR 112013024196A BR 112013024196 A2 BR112013024196 A2 BR 112013024196A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- pharmaceutical compositions
- complexes
- gallium
- gallium complexes
- Prior art date
Links
- 150000002258 gallium Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical group [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 229910052733 gallium Inorganic materials 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
- C07C59/50—Mandelic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
complexos de gálio, composições farmacêuticas e métodos de uso a presente invenção fornece complexos de gálio com um ligante, métodos de produção dos complexos, métodos de uso dos complexos e de composições farmacêuticas de gálio compreendendo os complexos, em particular aquelas composições adequadas para administração oral terapêuticas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161467170P | 2011-03-24 | 2011-03-24 | |
US201161515462P | 2011-08-05 | 2011-08-05 | |
US13/426,877 US20120245135A1 (en) | 2011-03-24 | 2012-03-22 | Gallium Complexes, Pharmaceutical Compositions And Methods Of Use |
PCT/US2012/030267 WO2012129473A1 (en) | 2011-03-24 | 2012-03-23 | Gallium complexes, pharmaceutical compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013024196A2 true BR112013024196A2 (pt) | 2016-12-13 |
Family
ID=46877850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013024196A BR112013024196A2 (pt) | 2011-03-24 | 2012-03-23 | complexos de gálio, composições farmacêuticas e métodos de uso |
Country Status (14)
Country | Link |
---|---|
US (2) | US20120245135A1 (pt) |
EP (1) | EP2688563B1 (pt) |
JP (1) | JP2014516348A (pt) |
KR (1) | KR20140053874A (pt) |
CN (1) | CN103732221A (pt) |
AU (1) | AU2012230834A1 (pt) |
BR (1) | BR112013024196A2 (pt) |
EA (1) | EA201391384A1 (pt) |
ES (1) | ES2628464T3 (pt) |
IL (1) | IL228439A0 (pt) |
MX (1) | MX2013010947A (pt) |
SG (1) | SG193495A1 (pt) |
TW (1) | TW201309647A (pt) |
WO (1) | WO2012129473A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI735652B (zh) * | 2016-09-29 | 2021-08-11 | 心悅生醫股份有限公司 | 麴酸之共晶和/或共熔結晶、包含其之組合物與用途 |
US10537661B2 (en) | 2017-03-28 | 2020-01-21 | DePuy Synthes Products, Inc. | Orthopedic implant having a crystalline calcium phosphate coating and methods for making the same |
US10537658B2 (en) | 2017-03-28 | 2020-01-21 | DePuy Synthes Products, Inc. | Orthopedic implant having a crystalline gallium-containing hydroxyapatite coating and methods for making the same |
WO2024043867A1 (en) * | 2022-08-20 | 2024-02-29 | Sinapu Llc | C60 histidine carnosine fumarates and use |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4315927A (en) * | 1980-08-08 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Dietary supplementation with essential metal picolinates |
US6004951A (en) | 1989-11-22 | 1999-12-21 | Bernstein; Lawrence Richard | Administration of gallium complexes of 3-hydroxy-4-pyrones to provide physiologically active gallium levels in a mammalian individual |
US5574027A (en) | 1989-11-22 | 1996-11-12 | Bernstein; Lawrence R. | Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones |
US5258376A (en) | 1989-11-22 | 1993-11-02 | Bernstein Lawrence R | Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones |
US5196412A (en) | 1991-03-06 | 1993-03-23 | Johnson Matthey, Inc. | Gallium compounds |
GB9111689D0 (en) | 1991-05-31 | 1991-07-24 | Johnson Matthey Plc | Gallium compounds |
WO1993002087A1 (en) | 1991-07-25 | 1993-02-04 | Les Laboratoires Meram | Gallium (iii) complexes, process for their obtention and pharmaceutical compositions containing them |
US6203822B1 (en) | 1996-09-03 | 2001-03-20 | University Of Iowa Research Foundation | Gallium-containing compounds for the treatment of infections caused by intracellular pathogens and pathogens causing chronic pulmonary infection |
US6582722B1 (en) * | 1999-09-13 | 2003-06-24 | Mac Farms, Inc. | Amino acid chelate for the effective supplementation of calcium, magnesium and potassium in the human diet |
AU2003279067A1 (en) | 2002-09-23 | 2004-04-08 | Genta Inc. | Tri(alkylcarboxylato) gallium (iii) products and pharmaceutical compositions containing them |
US7547454B2 (en) * | 2002-11-07 | 2009-06-16 | Shyam K Gupta | Hydroxy acid complexes for antiaging and skin renovation |
EP1601367A2 (en) * | 2003-02-06 | 2005-12-07 | Bioresponse L.L.C. | The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions |
EP1948159A4 (en) * | 2005-11-04 | 2011-10-12 | Genta Inc | PHARMACEUTICAL COMPOSITIONS OF GALLIUM AND METHODS |
US9103599B2 (en) | 2012-08-30 | 2015-08-11 | Wei-Ching Lee | Flake and method for reducing temperature of waste heat discharged from air conditioner |
-
2012
- 2012-03-22 US US13/426,877 patent/US20120245135A1/en not_active Abandoned
- 2012-03-23 SG SG2013069737A patent/SG193495A1/en unknown
- 2012-03-23 KR KR1020137028072A patent/KR20140053874A/ko not_active Application Discontinuation
- 2012-03-23 EP EP12719508.9A patent/EP2688563B1/en not_active Not-in-force
- 2012-03-23 TW TW101110105A patent/TW201309647A/zh unknown
- 2012-03-23 EA EA201391384A patent/EA201391384A1/ru unknown
- 2012-03-23 JP JP2014501265A patent/JP2014516348A/ja active Pending
- 2012-03-23 CN CN201280024822.2A patent/CN103732221A/zh active Pending
- 2012-03-23 MX MX2013010947A patent/MX2013010947A/es unknown
- 2012-03-23 WO PCT/US2012/030267 patent/WO2012129473A1/en active Application Filing
- 2012-03-23 BR BR112013024196A patent/BR112013024196A2/pt not_active IP Right Cessation
- 2012-03-23 ES ES12719508.9T patent/ES2628464T3/es active Active
- 2012-03-23 AU AU2012230834A patent/AU2012230834A1/en not_active Abandoned
-
2013
- 2013-09-15 IL IL228439A patent/IL228439A0/en unknown
-
2015
- 2015-01-26 US US14/605,493 patent/US20150175631A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL228439A0 (en) | 2013-12-31 |
EP2688563B1 (en) | 2017-03-15 |
US20150175631A1 (en) | 2015-06-25 |
MX2013010947A (es) | 2014-03-12 |
ES2628464T3 (es) | 2017-08-02 |
WO2012129473A1 (en) | 2012-09-27 |
EP2688563A1 (en) | 2014-01-29 |
KR20140053874A (ko) | 2014-05-08 |
SG193495A1 (en) | 2013-10-30 |
EA201391384A1 (ru) | 2014-02-28 |
AU2012230834A1 (en) | 2013-11-07 |
US20120245135A1 (en) | 2012-09-27 |
JP2014516348A (ja) | 2014-07-10 |
TW201309647A (zh) | 2013-03-01 |
CN103732221A (zh) | 2014-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
MX2013008851A (es) | Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. | |
TR201908596T4 (tr) | Spiro-laktam NMDA reseptörü modülatörleri ve bunların kullanımları. | |
AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
EA201390804A1 (ru) | Лекарственная форма лакозамида для приема один раз в сутки | |
EP3082797A4 (en) | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof | |
BR112015015891A8 (pt) | Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
BR112016000561B8 (pt) | Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma | |
BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
BR112016012506A2 (pt) | Combinações farmacêuticas, seus usos, e uso de um portador de dados | |
BR112014031310A2 (pt) | anticorpos anti-pcsk9, formulações, dosagem e métodos de uso | |
BR112014003802A2 (pt) | composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento | |
UY34350A (es) | Derivados de pirazolquinolinona, su preparación y su uso terapéutico. | |
AR090923A1 (es) | Anticuerpos anti-il-23 | |
TR201909447T4 (tr) | Aramkol tuzları. | |
EP3072506A4 (en) | Carrier for drug delivery and conjugate, composition containing same, and method for administering same | |
BR112015025814A2 (pt) | composição farmacêutica para uso inalatório, processo para a preparação de uma composição farmacêutica, composição sólida para uso como um diluente de pós para inalação e kit para a administração de um fármaco como pó para inalação | |
GT201200304A (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
BR112013024824A2 (pt) | ésteres isopentílicos para uso em composições cosméticas, dermatológicas ou farmacêuticas | |
BR112014002845A2 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto | |
BR112012022243A8 (pt) | Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico | |
UY34931A (es) | ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?. | |
BR112015006692A2 (pt) | formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |